Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies

@article{Horn2009FeasibilitySO,
  title={Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies},
  author={Biljana Horn and Sandeep Soni and Suranjita Khan and Aleksandra Petrovi{\'c} and Nancy Breslin and M J Cowan and G Pelle-Day and Emily Cooperstein and L. A. Baxter-Lowe},
  journal={Bone Marrow Transplantation},
  year={2009},
  volume={43},
  pages={469-476}
}
An increasing percentage of autologous cells (increasing chimerism) in the whole blood (WB) chimerism test following allogeneic transplant is related to a very high risk of relapse. Preemptive immunotherapy may decrease the risk of relapse in some patients. Our prospective multi-institutional study evaluated the feasibility of longitudinal chimerism testing in a central laboratory, compared WB, CD3+ and leukemia-specific lineage chimerism in patients with a variety of hematologic malignancies… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

predicts relapse in acute myeloid leukemia

  • J Mattson, M Uzunel, L Tammik, J Aschan, O Ringden
  • Bone Marrow Transplant
  • 2007

Similar Papers

Loading similar papers…